Cassandra Gorsuch, PhD, on the Durability and Next Steps for the ARCUS Gene Editing Platform in DMD
The chief scientific officer at Precision Biosciences discussed the durable potential of ARCUS gene editing and the company’s next steps toward in-human trials for Duchenne muscular dystrophy.
This video originally appeared on our sister site,
"With ARCUS, once the edit happens, it’s permanent—designed to outlast the vector and deliver a long-term, meaningful benefit for patients."
A severe X-linked disorder caused by mutations in the DMD gene, Duchenne muscular dystrophy (DMD) results in nonfunctional or absent dystrophin and progressive muscle degeneration. Typically, patients with the disease die in early adulthood. The therapeutic approaches currently available for the disorder, including gene therapies that deliver truncated, synthetic dystrophin constructs, have demonstrated only modest clinical benefit, and furthermore, in pediatric populations in particular may be held back by concerns related to durability. As such, the field has continued innovation with the exploration of gene editing approaches. One such example is Precision Biosciences' ARCUS-mediated gene editing platform.
By using 2 ARCUS nucleases, delivered using a single adeno-associated virus (AAV), to excise exons 45-55 of the dystrophin gene, this new approach is intended to bring about restoration of native dystrophin function. At
At the conference, CGTLive®'s sister site NeurologyLive® interviewed Cassandra Gorsuch, PhD, the chief scientific officer at Precision, about the company’s strategy in bringing this gene editing platform into clinical trials. She emphasized the approach’s durability, noting that once ARCUS edits the dystrophin gene, the change is permanent—even if the AAV delivery vector is later silenced or lost. Furthermore, Gorsuch highlighted the platform’s functional benefits, including its targeted exon 45-55 deletion strategy and potential to correct satellite stem cells for lasting effect.
REFERENCE
1. Mischler A, Owens G, Lewis W, et al. ARCUS-Mediated Excision of Exons 45-55 Leads to Functional Del45-55 Dystrophin and Restoration of Skeletal Muscle-Function for the Treatment of DMD. Presented at: 2025 MDA Clinical & Scientific conference; March 16-19; Dallas, TX. ABSTRACT 0159
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- Around the Helix: Cell and Gene Therapy Company Updates – September 17, 2025
September 17th 2025
- ImmunoLogic, Episode 6: "The Future of Personalized Cancer Vaccines”
September 15th 2025
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025